Replies to post #95728 on Biotech Values

[DewDiligence]

AIS gets 25% of any US license fees to BPAX plus royalties. AIS also owns the ROW rights. My concern here is that all signs IMO point to an outright sale of BPAX after positive p3 data, which would reduce the value to AIS somewhat.

Why would a buyout of BPAX adversely affect the LibiGel economics for AIS?